ASH 2018 | An exciting era for CAR T-cell therapy
Thanks for your feedback, this will help us improve our content for you!
Mohamad Mohty, MD, PhD, of the University Pierre & Marie Curie, Paris, France, discusses the promising translation of treatments, notably the efficacy and feasibility of CAR-T cell therapy outside the clinical trial setting. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Mohty also shares his excitement in the progression of next-generation allogeneic T-cell immunotherapies for the treatment of Epstein–Barr virus (EBV) associated post-transplant lymphoproliferative disorder (PTLD).
Get great new content delivered to your inboxSign up